Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 16/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22999928 | 0.81 | MAP4K4 (0.39) | NR1H2PIK3R1PIK3CAMAP4K4MAPT | |
| SCHEMBL30954006 | 0.75 | NR1H2 (0.41) | NR1H2PIK3R1PIK3CAMAPT | |
| SCHEMBL27458686 | 0.75 | NR1H2 (0.41) | NR1H2PIK3R1PIK3CAMAPT | |
| SCHEMBL23794836 | 0.75 | NR1H2 (0.39) | NR1H2MAPTMEN1KMT2A | |
| SCHEMBL26640067 | 0.75 | MAPT (0.45) | MAPT | |
| SCHEMBL23415871 | 0.75 | SMN1; SMN2 (0.41) | NR1H2MAPTMEN1KMT2A | |
| SCHEMBL22999763 | 0.75 | DDB1 (0.40) | NR1H2PIK3R1PIK3CAMAP4K4MAPT | |
| SCHEMBL25279581 | 0.74 | ESR2 (0.39) | NR1H2MEN1KMT2A | |
| SCHEMBL21594081 | 0.74 | SMN1; SMN2 (0.41) | NR1H2MAPTMEN1KMT2A | |
| SCHEMBL22803887 | 0.73 | NR1H2 (0.54) | NR1H2PIK3R1PIK3CAMAP4K4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | NR1H2 2066/4885PIK3R1 2885/4885PIK3CA 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.